

## Best-Value Medicine (Teriparatide): Movymia®

### Information for Healthcare Professionals

The MMP recommends Movymia® as a Best-Value Medicine (BVM) for teriparatide. Prescribing Movymia® will lead to significant savings for the health service.

The following presentations of Movymia®, available on the High Tech Arrangement, are recommended as a best-value medicine (BVM):

- Movymia® 20 micrograms (mcg)/80 microliters solution for injection starter pack (2.4 ml cartridge + 1 pen)
- Movymia® 20 micrograms (mcg)/80 microliters solution for injection cartridge.

#### Movymia®



- Each starter pack contains one cartridge and one re-usable pen.
- Each dose that the re-usable pen delivers contains 20 mcg of teriparatide in 80 microliters.
- Each cartridge contains 28 doses of 20 mcg of teriparatide.
- There is no latex present in the re-usable pen; Movymia® is therefore suitable for patients with a latex allergy.
- It is supplied as a colourless, clear solution.
- On the first occasion that a patient receives Movymia®, they should be supplied with the starter pack. A cartridge is provided for all further supplies, for insertion into the re-usable pen.
- Needles are not included in the Movymia packs and therefore they should be prescribed and dispensed separately.

#### Storage

- Movymia® should be stored in a refrigerator (2°C - 8°C). It should not be frozen. It should not be used if it is, or has been, frozen.
- The cartridge should be kept in the original outer package in order to protect it from light.
- After insertion of the cartridge into the re-usable pen, the combined pen and cartridge should be returned immediately to the refrigerator after use. After the first use, the cartridge should not be removed from the pen during the 28 days of usage.
- After administration of the first injection from a Movymia® cartridge, it may be stored inserted in the re-usable pen for a maximum of 28 days at 2°C - 8°C (i.e. in a refrigerator).
- The Movymia® cartridge should be disposed of after 28 days from the date of first administration, even if it is not completely empty. It should be removed from the re-usable pen at this stage.

### **Dose Administration**

- The patient information leaflet contains a very clear diagrammatic guide on how to administer a dose from the PFP.
- Each Movymia® cartridge and re-usable pen should be used by one patient only.
- Movymia® should not be used if solid particles appear, or if the solution is cloudy or coloured.
- The Movymia® re-usable pen must be primed each time a new cartridge is inserted. This is done by turning the dose knob clockwise until a droplet sign is visible on the dose display and pressing the push button. Detailed instructions are provided in the patient information leaflet.
- The re-usable pen does not need to be primed before each daily injection.
- A new, sterile needle must be used when administering each dose of teriparatide from the Movymia® re-usable pen.
- Needles are not supplied with Movymia® and therefore they should be prescribed and dispensed separately.
- The Movymia® re-usable pen can be used with pen needles of a gauge between 29 G and 31 G (diameter 0.25 – 0.33 mm) and a length between 5 mm to 12.7 mm.
- The Movymia® re-usable pen should be recapped when not in use.
- The needle should be removed and placed in a sharps bin after administration of each dose of teriparatide. The Movymia® re-usable pen should not be stored with a needle attached.
- The date of administration of the first injection from a Movymia® cartridge should be written in the provided space (*First use*) on the outer carton of Movymia®.
- When administration of a dose of teriparatide from the Movymia® is complete, the display window on the re-usable pen should return to the start position. If it does not return to the start position, a second dose should not be administered on the same day. The troubleshooting section of the patient information leaflet should be consulted for further advice.
- The Movymia® re-usable pen has a service life of two years.

### **Similarities between Movymia® and the reference biological medicine (Forsteo® pre-filled pen)**

- Movymia® cartridge and Forsteo® PFP have a shelf life of two years.
- After administration of the first injection from the pen device, both Movymia® and Forsteo® should be stored for a maximum of 28 days at 2°C - 8°C. After this time, the Movymia® cartridge and Forsteo® PFP should be disposed of, even if they are not completely empty.
- A new, sterile needle must be used when administering each dose of teriparatide from the Movymia® re-usable pen and Forsteo® PFP.
- Needles are not supplied with the Movymia® or Forsteo®.

### **Differences between Movymia® and the reference biological medicine (Forsteo® pre-filled pen)**

- The patient is supplied with a re-usable pen when they receive the Movymia® starter pack; a cartridge is provided for all further supplies, for insertion into the re-usable pen. Forsteo® PFP is a disposable PFP; the PFP and its contents are discarded 28 days after administration of the first injection from the PFP. A new PFP is then supplied to the patient.
- The Movymia® re-usable pen must be primed each time a new cartridge is inserted. Forsteo® PFP does not require priming prior to administration of the first dose from the PFPs.
- Movymia® re-usable pen and Forsteo® PFP have different indicators to show that administration of a dose of teriparatide is complete; for Movymia®, the display window on the re-usable pen returns to the start position. For Forsteo®, the black injection button should be all the way in, and the yellow shaft should not be visible.



### Clonmel Healthcare Limited Patient Support Services

Clonmel Healthcare Limited provide a patient support service to patients who have been prescribed Movymia<sup>®</sup>. This is provided nationally by the Clonmel Healthcare Limited nurse team, with the exception of the Munster region, where the service is provided by TCP Homecare on behalf of Clonmel Healthcare Limited.

The following services are available as part of the patient support service:

- Nurse home visit: Provision of up to two nurse home visits to deliver patient education and training on correct injection and administration technique for Movymia<sup>®</sup>.
- Sharps management service: This includes the provision of sharps bins and waste collection.
- Post-home visit education report shared with the referring healthcare professional
- Provision of follow-on phone support
- Provision of patient support materials, e.g. Patient Information Booklet, Patient Education Video
- Provision of cooler bag for traveling.

**In order to avail of the patient support services for patients who have been prescribed Movymia<sup>®</sup>, please complete and return the Movymia Patient Support Programme Referral Form to [homecare.pcb@tcp.ie](mailto:homecare.pcb@tcp.ie). Copies of the Movymia Patient Support Programme Referral Form can be requested by phoning 01 429 1820.**

In order to obtain training pens and patient support materials for use in clinics, please contact:

- Email: [info@clonmel-health.ie](mailto:info@clonmel-health.ie)
- Phone: 052 617 7777

#### References:

1. Movymia<sup>®</sup> 20 micrograms/80 microliters solution for injection. Summary of Product Characteristics. Last revised 20/01/2022. Accessed at [www.ema.europa.eu](http://www.ema.europa.eu) on 01/02/2023.